Recent studies detailing the possibilities of PARP10 inhibitors as anti-cancer agents have proven promising, showing that siRNA-targeted PARP10 repressed growth and metastatic capabilities in oral squamous cell carcinoma by negating its ability to regulate cell proliferation and apoptosis [117]. This evidence concerns the gene PARP10 and oral cavity squamous cell carcinoma.